Geneuro Sa

Centre National De La Recherche Scientifique

The United States of America, As Represented by the Secretary, Department of Health and Human Services

Biomerieux, Inc.

Universite Claude Bernard – Lyon1

Institut National De La Sante Et De La Recherche Medicale

Biomerieux Sa

Agence Francaise De Securite Sanitaire Des Aliments-afssa

Hervé Perron

Bernard F Mandrand

Glaucia Paranhos-Baccala

Florence Komurian-Pradel

Anthony William Coleman

Avindra Nath

Patrick Küry

Frédéric Bedin

Marc Rodrigue

Alois Bernhardt Lang

Patrice Marche

Joseph Perry Steiner

Julie Medina

Corinne Bernard

Jean-Baptiste Bertrand

Anne Eveno-Nobile

Wenxue Li

Raphaël Faucard

Nicole Battail-Poirot

Alexandra Madeira

Aly Moussa

Ambroise Martin

Julie Joanou

Patrick Shahgaldian

Reza Firouzi

Myoung-Hwa Lee

Sébastien Cecillon

Myound-Hwa Lee

Jacques Portoukalian

Anna Bencsik-Reynier

Evelyne Jouvin-Marche

Colette Jolivet Reynaud

François Curtin

Nadège Gehin

Alexandre Rolland

Frédéric Beseme

The present invention relates to a novel antibody against HERV-K envelope that targets a conserved region not affected by glycosylation or by native conformation, and its use in diagnostics and/or is therapy.

Anti-HERV-K envelope protein antibodies and methods for detecting HERV-K envelope protein in patients with sporadic amyotrophic lateral sclerosis

The present invention relates to a novel antibody against HERV-K envelope that targets a conserved region not affected by glycosylation or by native conformation, and its use in diagnostics and/or in therapy.

Methods for alleviating symptoms of sporadic amyotrophic lateral sclerosis by neutralizing a HERV-K envelope protein using an anti-HERV-K envelope protein antibody

The present invention deals with innovative compounds and compositions for preventing and/or treating a newly discovered detrimental mechanism, which blocks the endogenous myelin repair capacity of the adult nervous system (NS) in diseases associated with the expression of HERV-W envelope protein (ENV), in particular of its MSRV subtype.

Compounds for treating the remyelination blockade in diseases associated with the expression of HERV-W envelope protein

The present invention concerns a method for detecting aggregate-forming circulating protein forms in a biological sample of human origin that may contain said aggregate-forming circulating protein forms, characterized in that it uses a non-protein agent I producing aggregation of the circulating forms of the noninfectious proteins involved in pathological aggregation processes of the central nervous system and/or a non-protein agent II for capturing the natural aggregrates of aggregate-forming circulating protein forms or the aggregates induced by said agents I.

Method for detecting aggregate-forming circulating protein forms using an agent for aggregating said forms and an agent for capturing formed aggregates

The invention relates to an isolated cytotoxic factor which is associated with multiple sclerosis and which is selected from the heterocomplex GM2AP/GM2/MRP14 and mutated GM2AP/GM2/MRP14, and to the method of detecting said factor in a biological sample to be tested. The inventive method comprises the following steps consisting in: (i) bringing the biological sample into contact with at least one capture antibody selected from antibodies that bind specifically to the GM2AP protein, to the mutated GM2AP protein, to the MRP14 protein, to the complex GM2AP/GM2, to the complex mutated GM2AP/GM2 and to the complex MRP14/GM2, and with at least one labeled detection antibody selected from antibodies that bind specifically to the GM2AP protein, to the mutated GM2AP protein, to the MRP14 protein, to the complex GM2AP/GM2, to the complex mutated GM2AP/GM2 and to the complex MRP14/GM2, and (ii) detecting and/or quantifying the cytotoxic factor by detecting and/or quantifying the labeled detection antibody.

Method of isolating cytotoxic heterocomplex associated with multiple sclerosis

A process of concentration by precipitation of PrPfor detecting or diagnosing PrP, wherein a tissue or biological fluid stemming from or obtained from an animal or human organism is brought together with an antibiotic from the family of aminoglycosides, preferably streptomycin or one of its derivatives. The use of such an antibiotic for eliminating PrPfrom a tissue or biological fluid and a kit for diagnosing pathologies associated with the presence of PrPis also disclosed.

[object Object]

Growing community of inventors

Saint Genis les Ollieres, France

Hervé Perron